Vice President, Research & Development / Chief Scientific Officer, Medical Research Institute (MRI) 1999-2002 and 2002-2006. Provided scientific leadership/expertise in product development, manufacturing, QA, regulatory affairs, technology evaluation, and clinical trials for privately held, science-based nutrional supplement firm, with products marketed as NO2, CE2, AgeLess, and Glucotize. MRI was acquired by Natrol (NASDAQ: NTOL) in June, 2007.
Director, PreClinical Biology, Telik, Inc. 2000-2002. Directed process for selecting lead compounds for treatment of obesity and type 2 diabetes for startup biopharmaceutical firm.
Senior Scientist / Project Leader, Diabetes Program, SUGEN, Inc. 1996-1999. Provided scientific leadership for pre-clinical development activities to select lead compound for obesity and type 2 diabetes.
Senior Scientist, Diabetes Program, Shaman Pharmaceuticals 1994-1995. Instituted / managed cellular screening program, generating, interpreting and reporting pharmacology data. Provided expertise for nascent diabetes program.
Associate Fellow, Department of Metabolic Diseases, Novartis (formerly Sandoz Pharmaceuticals) 1990-1994. Identified / evaluated / validated drug targets in insulin signaling pathways as potential pharmacological opportunities for the treatment of type 2 diabetes.
Post-Doctoral Fellow, Dartmouth Medical School 1986-1990. Laboratory of Professor Lee A. Witters (Research Focus: Insulin signal transduction to glucose transport, hormonal reagulation of kinases, phosphatases, and lipid / carbohydrate metabolism.
Environmental Biologist, Merck, Inc. 1979-1981
Quality Assurance Manager, Syntex, Inc. 1974-1979